Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

NCT05853367 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Solid Tumors
Advanced Solid Tumors

Interventions

DRUG: MK-0472
BIOLOGICAL: Pembrolizumab
DRUG: MK-1084

Sponsor

Merck Sharp & Dohme LLC